CLOs on the Move

Avantra Biosciences FKA Decision Biomarkers

www.avantrabio.com

 
Avantra Biosciences FKA Decision Biomarkers, Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Feldan Therapeutics

Since its beginning, Feldan has valued internal research with the aim of innovating, changing standards of care and redefining quality of life. With the recent development of the Feldan Shuttle, this approach is starting to show its promises. Feldan`s mission is to develop regenerative medicine therapeutic applications based on Feldan`s proprietary technology.

Allylix Inc.

Allylix Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Bellen Health Care System

Bellen Health Care System is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Curie Co

Curie Co is replacing chemicals with clean, sustainable proteins and enzymes.

Deep Genomics

Our founding belief is that the future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. Today, the molecular world of the cell can be experimentally interrogated like never before. The resulting datasets provide an unprecedented opportunity to build artificial intelligence systems that are biologically accurate and that support the detection of disease and the development of molecular interventions. Deep Genomics is building a biologically accurate data- and AI-driven platform that supports geneticists, molecular biologists and chemists in the development of therapies. Over the next two years, Deep Genomics will use its platform to unlock new classes of antisense oligonucleotide therapies that were previously inaccessible or out of reach, and advance them for clinical evaluation. In project Saturn, the platform will be used to search across a vast space of over 69 billion molecules with the goal of generating a library of 1000 compounds that can be used to manipulate cell biology and design therapies.